Trial reportBMC ophthalmology2026
Okra eyelid patch versus sodium hyaluronate combined with ofloxacin eye drop in the treatment of meibomian gland dysfunction: a randomized controlled trial.
Trial report in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate the clinical efficacy of okra eyelid patch versus sodium hyaluronate combined with ofloxacin eye drop in the treatment of patients suffering from meibomian gland dysfunction (MGD).
methods40 patients included were randomly divided into 2 groups: okra eyelid patch group (n = 20) and control group (n = 20). Before treatment, on the 14th and 28th day of treatment, the following ophthalmic examinations were performed: symptoms and signs score, Schirmer I test (SIT), tear film break-up time (TBUT), corneal fluorescein staining (CFS), optical quality analysis system (OQAS II) and ocular surface interferometer examination. Ocular surface disease index (OSDI) questionnaire score and in vivo confocal microscopy (IVCM) were performed before treatment and on the 28th day of treatment. Adverse effects were reported during the treatment period. Results were analyzed by SPSS 25.0 software. p < 0.05 was considered a statistically significant difference.
resultsOn day 28, okra eyelid patch group had a better curative effect in symptoms score, signs score, total score, OSDI questionnaire score, TBUT, and CFS score, lipid layer thickness and MASD compared with control group (p < 0.05). During the 28-day treatment, one patient in okra eyelid patch group reported eyelid redness, while the difference between the two groups was not statistically significant (p > 0.05).
conclusionsOkra eyelid patch has a more significant effect on MGD, especially in improving symptoms and signs, increasing lipid layer thickness, improving tear film stability, maintaining corneal epithelial integrity, and improving the quality of meibomian gland acini compared with artificial tears combining ofloxacin eye drops. It has few side effects, and provides a new therapeutic option for MGD associated with dry eye.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.